Aligos Therapeutics Inc (ALGS)
0.818
-0.01
(-1.33%)
USD |
NASDAQ |
Apr 25, 16:00
0.8012
-0.02
(-2.05%)
After-Hours: 20:00
Aligos Therapeutics Cash from Financing (Quarterly): 87.94M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 87.94M |
| September 30, 2023 | -0.021M |
| June 30, 2023 | 0.414M |
| March 31, 2023 | -0.001M |
| December 31, 2022 | 0.121M |
| September 30, 2022 | -0.019M |
| June 30, 2022 | 0.083M |
| March 31, 2022 | -0.021M |
| Date | Value |
|---|---|
| December 31, 2021 | 0.552M |
| September 30, 2021 | 77.95M |
| June 30, 2021 | 0.095M |
| March 31, 2021 | 0.078M |
| December 31, 2020 | 193.32M |
| September 30, 2020 | -0.949M |
| June 30, 2020 | 0.027M |
| March 31, 2020 | -0.048M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.949M
Minimum
Sep 2020
193.32M
Maximum
Dec 2020
22.47M
Average
0.0805M
Median
Cash from Financing (Quarterly) Benchmarks
| Mirum Pharmaceuticals Inc | 1.777M |
| CEL-SCI Corp | 4.048M |
| AIM ImmunoTech Inc | 0.147M |
| IGC Pharma Inc | -0.001M |
| NovaBay Pharmaceuticals Inc | -0.026M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -22.66M |
| Cash from Investing (Quarterly) | -0.007M |
| Free Cash Flow | -79.02M |
| Free Cash Flow Per Share (Quarterly) | -0.3018 |
| Free Cash Flow to Equity (Quarterly) | -22.66M |
| Free Cash Flow to Firm (Quarterly) | -21.20M |
| Free Cash Flow Yield | -188.7% |